AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2272957 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Polycose)
Number of subjects: 8
Study 7377861 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 48
Study 7377861 — intervention group
Group type: COMPARATOR
Intervention: No levamisole or placebo (Control)
Number of subjects: 48
Study 31438849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarming at 43 °C during epidural catheter placement
Number of subjects: 47
Study 31438849 — intervention group
Group type: COMPARATOR
Intervention: No prewarming
Number of subjects: 47
Study 28185468 — intervention group
Group type: EXPERIMENTAL
Intervention: Early precut (group A)
Number of subjects: 101
Study 28185468 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic duct stent (group B)
Number of subjects: 101
Study 26562491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the PLEASANT trial
Number of subjects: 142
Study 26562491 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous randomised controlled trial involvement
Number of subjects: 142
Study 26562491 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of studies a practice had previously engaged in
Number of subjects: 142
Study 26562491 — intervention group
Group type: COMPARATOR
Intervention: Practice size
Number of subjects: 142
Study 23123345 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg/day) for 23 days followed by doxycycline (200mg/day) in combination with albendazole (ABZ) (400mg/day) for 7 days
Number of subjects: 68
Study 23123345 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg/day) alone
Number of subjects: 68
Study 23123345 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) (400mg/day) alone
Number of subjects: 68
Study 23123345 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline combined with ABZ
Number of subjects: 68
Study 23123345 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day regimen of ABZ
Number of subjects: 68
Study 23123345 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and ABZ in combination
Number of subjects: 68
Study 21785478 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrodiscal approach TFESI
Number of subjects: 40
Study 21785478 — intervention group
Group type: COMPARATOR
Intervention: Classic approach TFESI
Number of subjects: 40
Study 19514296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapeutic modalities with magnetopuncture therapy
Number of subjects: 0
Study 19514296 — intervention group
Group type: COMPARATOR
Intervention: Combined therapeutic modalities without magnetopuncture therapy
Number of subjects: 0
Study 16691061 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate (CS) gel
Number of subjects: 59
Study 16691061 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 59
Study 15585061 — intervention group
Group type: EXPERIMENTAL
Intervention: Half‐day critical appraisal skills training workshop
Number of subjects: 145
Study 15585061 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 145
Study 11350571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nimodipine (2-mg h(-1))
Number of subjects: 265
Study 11350571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nimodipine (1-mg h(-1))
Number of subjects: 265
Study 11350571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 8498421 — intervention group
Group type: EXPERIMENTAL
Intervention: 587 mg calcium per day
Number of subjects: 10
Study 8498421 — intervention group
Group type: EXPERIMENTAL
Intervention: 1336 mg calcium per day
Number of subjects: 10
Study 8498421 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg manganese per day
Number of subjects: 10
Study 8498421 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.6 mg manganese per day
Number of subjects: 10
Study 2958819 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg intramuscularly and intravenously
Number of subjects: 276
Study 2958819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 276
Study 31885292 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmitted patients (5.29% of total population)
Number of subjects: 1702
Study 31885292 — intervention group
Group type: EXPERIMENTAL
Intervention: History of eczema
Number of subjects: 1702
Study 31885292 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mycoplasma pneumoniae (MP) antibody IgM
Number of subjects: 1702
Study 31913413 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel alone or with carboplatin and/or veliparib for 12 weeks followed by 4 cycles of doxorubicin hydrochloride and cyclophosphamide
Number of subjects: 634
Study 31913413 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel alone or with carboplatin and/or veliparib
Number of subjects: 634
Study 30231642 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC training for peers
Number of subjects: 12
Study 30231642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study 27846875 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach for THA
Number of subjects: 0
Study 27846875 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral approach for THA
Number of subjects: 0
Study 25372086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (25 mg etanercept plus methotrexate)
Number of subjects: 306
Study 25372086 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 306
Study 25372086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 23055132 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training (GT)
Number of subjects: 124
Study 23055132 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training (IT)
Number of subjects: 124
Study 21740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased brain activity in left supramarginal and angular gyri, superior and middle temporal gyri in Adequate Responders (AR)
Number of subjects: 50
Study 21740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline activation profiles of AR group
Number of subjects: 50
Study 21740612 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 18637924 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis procedure
Number of subjects: 100
Study 18637924 — intervention group
Group type: COMPARATOR
Intervention: Limberg procedure
Number of subjects: 100
Study 18637924 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 100
Study 16549707 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-injection site pattern (3 injections of 10 U of botulinum toxin A)
Number of subjects: 221
Study 16549707 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-injection site pattern (5 injections of 10 U of botulinum toxin A)
Number of subjects: 221
Study 16549707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 injections)
Number of subjects: 221
Study 16549707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 injections)
Number of subjects: 221
Study 12892319 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 12892319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oils
Number of subjects: 0
Study 12892319 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 12892319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 11156724 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 11156724 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 11156724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enoxaparin and abciximab
Number of subjects: 0
Study 9052285 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of dexamethasone
Number of subjects: 38
Study 9052285 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 38
Study 8112474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with no supplemental oxygen
Number of subjects: 212
Study 8112474 — intervention group
Group type: EXPERIMENTAL
Intervention: No sedation and no oxygen supplementation
Number of subjects: 212
Study 8112474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation and supplemental oxygen
Number of subjects: 212
Study 8112474 — intervention group
Group type: COMPARATOR
Intervention: No sedation but supplemental oxygen
Number of subjects: 212
Study 3061292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus prednisone (C+P)
Number of subjects: 32
Study 3061292 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine plus prednisone (A+P)
Number of subjects: 32
Study 3061292 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (C)
Number of subjects: 32
Study 3061292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30990088 — intervention group
Group type: EXPERIMENTAL
Intervention: Group parent and adolescent skills training (STAND)
Number of subjects: 123
Study 30990088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic skills training blended with motivational interviewing (STAND)
Number of subjects: 123
Study 30990088 — intervention group
Group type: COMPARATOR
Intervention: Group models (STAND)
Number of subjects: 123
Study 30990088 — intervention group
Group type: COMPARATOR
Intervention: Dyadic treatment (STAND)
Number of subjects: 123
Study 29091530 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60% of 1-repetition maximum
Number of subjects: 11
Study 29091530 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 72% of 1-repetition maximum
Number of subjects: 11
Study 29091530 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% of 1-repetition maximum
Number of subjects: 11
Study 27197965 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS) calculated from 29 prostate cancer risk-associated SNPs
Number of subjects: 4528
Study 27197965 — intervention group
Group type: COMPARATOR
Intervention: Family History (FH)
Number of subjects: 4528
Study 27197965 — intervention group
Group type: EXPERIMENTAL
Intervention: FH+ or GRS >1.4
Number of subjects: 4528
Study 27197965 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting FH+ or GRS >1.4 men
Number of subjects: 4528
Study 25564411 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone (Group A)
Number of subjects: 85
Study 25564411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy combined with lymphadenectomy (Group B)
Number of subjects: 85
Study 25564411 — intervention group
Group type: COMPARATOR
Intervention: Surgical complications (Group A)
Number of subjects: 85
Study 25564411 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications (Group B)
Number of subjects: 85
Study 23759461 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,500 mg/d
Number of subjects: 55
Study 23759461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19796088 — intervention group
Group type: EXPERIMENTAL
Intervention: Li-PDT-PC (5-ALA 0.5% liposomal spray and intense pulsed light in combination with topical peeling agents)
Number of subjects: 32
Study 19796088 — intervention group
Group type: COMPARATOR
Intervention: Li-PDT-PC-AT (Li-PDT-PC with additional topical or systemic antibiotics)
Number of subjects: 32
Study 18428095 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication treatment plus three-weekly CM sessions for 5 weeks
Number of subjects: 43
Study 18428095 — intervention group
Group type: COMPARATOR
Intervention: CM sessions
Number of subjects: 43
Study 16804925 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 16804925 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 16804925 — intervention group
Group type: COMPARATOR
Intervention: Prior chemotherapy
Number of subjects: 0
Study 12563672 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (0.04, 0.1, 0.4, 1, or 2 mg/kg once daily for 24 weeks)
Number of subjects: 419
Study 12563672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in addition to MTX 15 to 25 mg/wk)
Number of subjects: 419
Study 10100069 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to famine during late gestation (n = 120)
Number of subjects: 739
Study 10100069 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to famine during mid-gestation (n = 109)
Number of subjects: 739
Study 10100069 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to famine during early gestation (n = 68)
Number of subjects: 739
Study 10100069 — intervention group
Group type: COMPARATOR
Intervention: Unexposed subjects (n = 442)
Number of subjects: 739
Study 10100069 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight increase
Number of subjects: 739
Study 9156926 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 30
Study 1862257 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg t.i.d.) for 8 days
Number of subjects: 16
Study 1862257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6814281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 33
Study 6814281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31693746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral monitoring awareness (Group 2)
Number of subjects: 80
Study 31693746 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure treatment only (Group 1)
Number of subjects: 80
Study 31527283 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 370771
Study 31527283 — intervention group
Group type: EXPERIMENTAL
Intervention: Automobile speed propensity
Number of subjects: 370771
Study 31527283 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 370771
Study 28422369 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire (4 A4 pages)
Number of subjects: 4241
Study 28422369 — intervention group
Group type: COMPARATOR
Intervention: Long questionnaire (7 A4 pages)
Number of subjects: 4241
Study 28422369 — intervention group
Group type: EXPERIMENTAL
Intervention: £2.50 shop voucher incentive
Number of subjects: 4241
Study 28422369 — intervention group
Group type: EXPERIMENTAL
Intervention: £5.00 shop voucher incentive
Number of subjects: 4241
Study 28422369 — intervention group
Group type: EXPERIMENTAL
Intervention: £250 shop voucher prize draw incentive
Number of subjects: 4241
Study 28422369 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 4241
Study 25885923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricing intervention (10-30% price discount on selected healthier food items)
Number of subjects: 360
Study 25885923 — intervention group
Group type: EXPERIMENTAL
Intervention: Communications intervention (visual and interactive materials to promote healthy items)
Number of subjects: 360
Study 25885923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (pricing and communications)
Number of subjects: 360
Study 25885923 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 360
Study 24059983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive integrative language therapy (at least 2 hours/day and at least 10 hours/week for at least three weeks)
Number of subjects: 126
Study 24059983 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (untreated)
Number of subjects: 126
Study 21410882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified complementary or replacement foods provided free of charge
Number of subjects: 811
Study 21410882 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker advice
Number of subjects: 811
Study 21410882 — intervention group
Group type: EXPERIMENTAL
Intervention: International HIV and infant feeding recommendations
Number of subjects: 811
Study 21410882 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement feeding
Number of subjects: 811
Study 21410882 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative factors affecting decisions
Number of subjects: 811
Study 19522426 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin 850 mg two times a day
Number of subjects: 32
Study 19522426 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 32
Study 17308899 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpadronate (10 mg/m2/day)
Number of subjects: 34
Study 17308899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 1 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 3 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 10 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 30 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 100 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 150 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391 200 mg
Number of subjects: 53
Study 14973308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-96391
Number of subjects: 53
Study 14973308 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-100014 (metabolite)
Number of subjects: 53
Study 11676271 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 104
Study 9054234 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mg/day nicotine patches
Number of subjects: 522
Study 9054234 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 522
Study 9054234 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-mg/day nicotine patches
Number of subjects: 522
Study 9054234 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mg/day nicotine patches
Number of subjects: 522
Study 7946592 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + MPA therapy (CAF: CPA 100 mg orally days 1-14, ADR 30 mg/m2 i.v. days 1 and 8, 5-FU 500 mg/m2 i.v. days 1 and 8; MPA 1200 mg daily)
Number of subjects: 168
Study 7946592 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + MPA therapy
Number of subjects: 168
Study 7946592 — intervention group
Group type: COMPARATOR
Intervention: CAF therapy (control)
Number of subjects: 168
Study 2840000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 20
Study 31868099 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% velocity loss
Number of subjects: 12
Study 31868099 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% velocity loss
Number of subjects: 12
Study 31868099 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% velocity loss
Number of subjects: 12
Study 31868099 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ) variables
Number of subjects: 12
Study 29439648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 5/5 µg
Number of subjects: 404
Study 29439648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 2.5/5 µg
Number of subjects: 404
Study 29439648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 28940037 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 18
Study 28940037 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise (resistance and plyometric exercise)
Number of subjects: 18
Study 26303634 — intervention group
Group type: COMPARATOR
Intervention: Weekend admission
Number of subjects: 533
Study 26303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-weekend admission
Number of subjects: 533
Study 26303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Thursday/Friday Norwood procedure
Number of subjects: 533
Study 26303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatally diagnosed infants born on the weekend
Number of subjects: 533
Study 23008090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip SMBG
Number of subjects: 137
Study 23008090 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm SMBG
Number of subjects: 137
Study 23008090 — intervention group
Group type: COMPARATOR
Intervention: No SMBG
Number of subjects: 137
Study 21633921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of circulating progenitor cells (CPC) or bone marrow-derived progenitor cells (BMC)
Number of subjects: 59
Study 18350925 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotopic cardiac transplantation
Number of subjects: 0
Study 18350925 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and radiotherapy
Number of subjects: 0
Study 18350925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive surgical management for secondary cardiac involvement
Number of subjects: 0
Study 18350925 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy, radiotherapy, and surgery
Number of subjects: 0
Study 16292634 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine Tango registry
Number of subjects: 0
Study 16292634 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 16292634 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study 12727705 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24
Study 12727705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12388895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0
Study 8840060 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sevoflurane inspired in oxygen
Number of subjects: 29